Graves Ophthalmopathy - Pipeline Insight, 2024

Graves Ophthalmopathy - Pipeline Insight, 2024

DelveInsight’s, “Graves Ophthalmopathy - Pipeline Insight, 2024,” report provides comprehensive insights about 6+ companies and 6+ pipeline drugs in Graves Ophthalmopathy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Graves Ophthalmopathy Understanding

Graves Ophthalmopathy: Overview

Graves’ eye disease, also called Graves’ Ophthalmopathy or Thyroid Eye disease, is a problem that usually develops in people with an overactive thyroid caused by Graves’ disease (See brochure on Graves’ disease). Graves’ disease is an autoimmune disease caused by antibodies directed against receptors present in the thyroid cells and also on the surface of the cells behind the eyes. Rarely can also affect the skin, usually the front part of the legs. This usually results in a generalized over activity of the thyroid gland (hyperthyroidism). Up to one-half of people with Graves’ disease develop eye symptoms. These are usually mild and treatable. Eye symptoms most often begin within 6 months of diagnosis of Graves’ disease. Very rarely eye problems may develop long after the thyroid disease has been treated. In some patients with eye symptoms, hyperthyroidism never develops and, rarely, patients may be hypothyroid. The severity of the eye symptoms is not related to the severity of the hyperthyroidism.

""Graves Ophthalmopathy - Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Graves Ophthalmopathy pipeline landscape is provided which includes the disease overview and Graves Ophthalmopathy treatment guidelines. The assessment part of the report embraces, in depth Graves Ophthalmopathy commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Graves Ophthalmopathy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• A better understanding of disease pathogenesis contributing to the development of novel therapeutics for Graves Ophthalmopathy.
• In the coming years, the Graves Ophthalmopathy market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies and academics that are working to assess challenges and seek opportunities that could influence Graves Ophthalmopathy R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
• A detailed portfolio of major pharma players who are involved in fueling the Graves Ophthalmopathy treatment market. Several potential therapies for Graves Ophthalmopathy are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Graves

Ophthalmopathy market size in the coming years.

• Our in-depth analysis of the pipeline assets (in early-stage, mid-stage and late stage of development for the treatment of Graves Ophthalmopathy) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Graves Ophthalmopathy Emerging Drugs Chapters

This segment of the Graves Ophthalmopathy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Graves Ophthalmopathy Emerging Drugs

• Secukinumab: Novartis

Secukinumab is a fully human monoclonal IgG1/κ antibody against interleukin-17A (IL-17A), a proinflammatory cytokine implicated in various chronic immune-mediated inflammatory disorders, such as plaque psoriasis. By blocking the actions of IL-17A, secukinumab works to inhibit the pro-inflammatory pathways that drive immune-mediated inflammatory disorders. Following its first global approval in Japan in December 2014, secukinumab was approved by the European Commission on January 15, 2015, and by the FDA a few days after (January 21, 2015). It is currently approved to treat a number of chronic inflammatory conditions, such as plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis. Currently, it is in Phase III stage of clinical trial evaluation to treat Graves’ ophthalmopathy.

• Batoclimab (HBM9161): Harbour BioMed

Batoclimab (HBM9161) is a novel, fully human anti-FcRn mAb blocking FcRn-IgG interactions and accelerating the degradation of autoantibodies. HBM licensed batoclimab (HBM9161) from HanAll Biopharma and has the right to develop, manufacture and commercialize in Greater China (including Hong Kong, Macau and Taiwan). Currently, it is in Phase II/III stage of clinical trial evaluation to treat Graves’ ophthalmopathy.

Further product details are provided in the report……..

Graves Ophthalmopathy: Therapeutic Assessment

This segment of the report provides insights about the different Graves Ophthalmopathy drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Graves Ophthalmopathy

There are approx. 6+ key companies which are developing the therapies for Graves Ophthalmopathy. The companies which have their Graves Ophthalmopathy drug candidates in the most advanced stage, i.e. phase III include, Novartis.

• Phases

DelveInsight’s report covers around 6+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Graves Ophthalmopathy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Inhalation
• Inhalation/Intravenous/Oral
• Intranasal
• Intravenous
• Intravenous/ Subcutaneous
• NA
• Oral
• Oral/intranasal/subcutaneous
• Parenteral
• Subcutaneous
• Molecule Type

Products have been categorized under various Molecule types such as

• Antibody
• Antisense oligonucleotides
• Immunotherapy
• Monoclonal antibody
• Peptides
• Protein
• Recombinant protein
• Small molecule
• Stem Cell
• Vaccine
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Graves Ophthalmopathy: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Graves Ophthalmopathy therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Graves Ophthalmopathy drugs.

Graves Ophthalmopathy Report Insights

• Graves Ophthalmopathy Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Graves Ophthalmopathy Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Graves Ophthalmopathy drugs?
• How many Graves Ophthalmopathy drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Graves Ophthalmopathy?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Graves Ophthalmopathy therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Graves Ophthalmopathy and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Novartis
• Harbour BioMed
• Viridian Therapeutics, Inc.
• Suzhou Suncadia Biopharmaceuticals Co., Ltd.
• Sling Therapeutics, Inc.
• ValenzaBio
• Argenx
• HanAll Biopharma

Key Products

• Secukinumab
• Batoclimab
• VRDN-001
• SHR-1314
• Linsitinib
• VB421
• Efgartigimod
• HL036